Skip to main content

Table 1 Inclusion and exclusion criteria

From: Differentiated models of service delivery for antiretroviral treatment of HIV in sub-Saharan Africa: a rapid review protocol

A. Population• All ages
• All genders
• Confirmed HIV positive status
• All risk groups (general, priority, key)
• On any line of lifelong antiretroviral treatment (i.e., first, second, or third-line)
• In sub-Saharan Africa
• Pregnant women in PMTCT programs
• On ART for prevention (PEP or PrEP)
B. Intervention• Delivery of lifelong ART that differs from standard or traditional care in terms of population, location, frequency, provider cadre, or services provided.Report about a solely standard or traditional model for delivering ART, prior to any differentiation based on population, location, frequency, provider cadre, or services provided
C. Required descriptive data about modelReports all of
• Location—is care provided in the clinic, on the clinic campus, in the community or workplace, at home?
• Frequency—how often does the patient interact with the healthcare system for each type of service (drug pickup, medical consultation)?
• Provider—which cadre of clinical or lay staff provides the service? For example, nurses conduct the medical visits, while “expert patients” deliver drugs to the patient’s house.
• Patient type and line (stable, newly initiated, not stable; first, second, or third line)
• Services provided (visit intensity)—what occurs at each visit or interaction? Does visit include concomitant care or medication delivery for co-morbidities?
Description provided does not describe all the characteristics needed to define the model
D. ComparatorNot required—single-arm evaluations are eligibleNone
E. OutcomesReports one or more of the following outcomes:
• Coverage of population in need
• Uptake by patients
• Clinical outcome (e.g. retention in care, viral suppression)
• Cost or resource allocation
• Acceptability to patients or providers
• Feasibility to implement
Insufficient detail provided to estimate at least one outcome
F. TimingA majority of follow up data report on the delivery of antiretroviral treatment occurring in January 2016 or laterA majority of follow-up data report on the period before January 2016
G. SectorServices provided to the public sector through the government managed public health infrastructure or through partner/NGO/private programs or facilities that serve the uninsured sectorServices or programs for privately (commercially) insured patients
H. Study designReports empirical data from retrospective or prospective cohort, including:
• Randomized controlled trials
• Observational studies (including single-arm evaluations)
• Pre/post studies with or without a comparison group
• Systematic or other reviews
• Case series or reports
• Treatment guidelines
• Mathematical models
• Editorials
• Commentaries